A novel method for the determination of the site of glucuronidation by ion mobility spectrometry-mass spectrometry

Drug Metabolism and Disposition

Volumn 40, Issue 8, 2012, Pages 1456-1459

  Shimizu, Atsushi ^a   Ohe, Tomoyuki ^b   Chiba, Masato ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYL DERIVATIVE; ESTRADIOL; EZETIMIBE; LOSARTAN; PHENOLIC GLUCURONIDE CONJUGATE; RALOXIFENE; SCH 60663; TELMISARTAN; UNCLASSIFIED DRUG;

ACCURACY; ANALYTICAL PARAMETERS; ARTICLE; COLLISION CROSS SECTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG GLUCURONIDATION; HUMAN; HUMAN CELL; ION MOBILITY SPECTROMETRY; LIVER CELL; MASS SPECTROMETRY; PRIORITY JOURNAL;

CHROMATOGRAPHY, LIQUID; GLUCURONIDES; TANDEM MASS SPECTROMETRY;

EID: 84863904461     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.045435     Document Type: Article

References (21)

1. Baer BR, DeLisle RK, and Allen A (2009) Benzylic oxidation of gemfibrozil-1-O-β-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition. Chem Res Toxicol 22:1298-1309.
2. Benet LZ, Spahn-Langguth H, Iwakawa S, Volland C, Mizuma T, Mayer S, Mutschler E, and Lin ET (1993) Predictability of the covalent binding of acidic drugs in man. Life Sci 53:PL141-PL146.
3. Biancotto G, Angeletti R, Traldi P, Silvestri M, Saccon M, and Guidugli F (2002) Determination of 17 β-estradiol in bovine plasma: development of a highly sensitive technique by ion trap gas chromatography-tandem mass spectrometry using negative chemical ionization. J Mass Spectrom 37:1266-1271.
4. Dear GJ, Munoz-Muriedas J, Beaumont C, Roberts A, Kirk J, Williams JP, and Campuzano I (2010) Sites of metabolic substitution: investigating metabolite structures utilising ion mobility and molecular modelling. Rapid Commun Mass Spectrom 24:3157-3162.
5. Dodge JA, Lugar CW, Cho S, Short LL, Sato M, Yang NN, Spangle LA, Martin MJ, Phillips DL, Glasebrook AL, et al. (1997) Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. J Steroid Biochem Mol Biol 61:97-106.
6. Honkalammi J, Niemi M, Neuvonen PJ, and Backman JT (2011) Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic. Drug Metab Dispos 39:1977-1986.
7. Jarrold MF (2000) Peptides and proteins in the vapor phase. Annu Rev Chem 51:179-207.
8. Jarrold MF (2007) Helices and sheets in vacuo. Phys Chem Chem Phys 9:1659-1671.
9. Jenkins SM, Zvyaga T, Johnson SR, Hurley J, Wagner A, Burrell R, Turley W, Leet JE, Philip T, and Rodrigues AD (2011) Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-β-glucuronide of gemfibrozil. Drug Metab Dispos 39:2421-2430.
10. Kanu AB, Dwivedi P, Tam M, Matz L, and Hill HH Jr (2008) Ion mobility-mass spectrometry. J Mass Spectrom 43:1-22.
11. Kemp DC, Fan PW, and Stevens JC (2002) Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystematic clearance. Drug Metab Dispos 30:694-700.
12. Kroemer HK and Klotz U (1992) Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet 23:292-310.
13. Mesleh NF, Hunter JM, Schvartsburg AA, Schatz GC, and Jarrold MF (1996) Structural information from ion mobility measurements: effects of the long-range potential. J Phys Chem 100: 16082-16086.
14. Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y, Statkevich P, Iannucci R, Chowdhury S, Affrime M, et al. (2002) Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 30:430-437.
15. Ritter JK (2000) Roles of glucuronidation and UDP- glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 129:171-193.
16. van Dorp EL, Romberg R, Sarton E, Bovill JG, and Dahan A (2006) Morphine-6-glucuronide: morphine's successor for postoperative pain relief? Anesth Analg 102:1789-1797.
17. Regan SL, Maggs JL, Hammond TG, Lambert C, Williams DP, and Park BK (2010) Acyl glucuronides: the good, the bad and the ugly. Biopharm Drug Dispos 31:367-395.
18. Shipkova M and Wieland E (2005) Glucuronidation in therapeutic drug monitoring. Clin Chim Acta 358:2-23.
19. Smith DP, Knapman TW, Campuzano I, Malham RW, Berryman JT, Radford SE, and Ashcroft AE (2009) Deciphering drift time measurements from travelling wave ion mobility spectrometry- mass spectrometry studies. Eur J Mass Spectrom (Chichester, Eng) 15:113-130.
20. Williams JP, Lough JA, Campuzano I, Richardson K, and Sadler PJ (2009a) Use of ion mobility mass spectrometry and a collision cross-section algorithm to study an organometallic ruthenium anticancer complex and its adducts with a DNA oligonucleotide. Rapid Commun Mass Spectrom 23:3563-3569.
21. Williams JP, Bugarcic T, Habtemariam A, Giles K, Campuzano I, Rodger PM, and Sadler PJ (2009b) Isomer separation and gas-phase configurations of organoruthnium anticancer complexes: ion mobility mass spectrometry and modeling. J Am Soc Mass Spectrom 20:1119-1122.